Introduction
Novo Group recently hosted its inaugural India Day in Bengaluru, showcasing its enduring commitment to improving health, science, and sustainability in India. This event brought together leaders from across the Novo Group, including Novo Holdings, Novo Nordisk, and Novonesis, along with industry partners, academic institutions, and policy-makers. The gathering highlighted the extensive engagement of the Group with India, emphasizing the importance of collaboration in addressing healthcare challenges.
A United Front in Healthcare Innovation
India stands out as the only country outside Denmark where all four entities of the Novo Group maintain a robust presence. This includes the Novo Nordisk Foundation, Novo Holdings, Novo Nordisk, and Novonesis, each contributing to philanthropy, pharmaceutical innovation, healthcare investments, and biosolutions. The theme of the India Day, “From Innovation to Impact in India and Beyond,” encapsulated the shared vision of fostering a sustainable healthcare landscape.
The event commenced with an engaging fireside chat led by Dr. Amit Kakar, managing partner and head of Asia at Novo Holdings, alongside Dr. Monika Sharma, head of the Novo Nordisk Foundation’s India office. Their discussion centered on the intersection of philanthropy and investment, setting the stage for the day’s activities.
Keynote Insights and Panel Discussions
Following the opening conversation, representatives from each entity delivered keynote speeches, reflecting on their distinct contributions to India’s healthcare landscape. The event also featured panel discussions that focused on healthcare innovation and the essential infrastructure required for the future of health in India. Notably, CEOs from four Novo Holdings portfolio companies in India—MedGenome, Surya Hospitals, SCHOTT Poonawalla, and Medi Assist—participated in these discussions, sharing their insights on the dynamic healthcare environment.
Dr. Amit Kakar emphasized the strategic significance of India within Novo Holdings’ broader Asia strategy. He noted that healthcare expenditure in India is projected to nearly quadruple in the coming decade, with a rapidly expanding innovation base. This growth positions India as a critical pillar for the Group, reinforcing their long-term commitment to developing partnerships with leading healthcare and life sciences entities in the region.
Transforming Care Through Innovation
Vikrant Shrotriya, managing director of Novo Nordisk India, articulated the integral role India plays in realizing the full value chain of Novo Nordisk’s operations. He highlighted the company’s efforts to advance care for individuals living with diabetes, obesity, and other chronic conditions. Shrotriya pointed out that India is not merely a market; it serves as a strategic partner in driving healthcare innovation and improved patient outcomes globally.
The commitment to innovation is evident in Novo Nordisk’s pioneering initiatives, which include advancements in managing diabetes and obesity. The introduction of breakthrough treatments, such as semaglutide and once-weekly insulin, underscores the company’s dedication to bringing effective solutions closer to patients.
Biosolutions and Sustainable Growth
Krishna Mohan, regional president for the Middle East, India, and Africa at Novonesis, discussed India’s ambitions to evolve into a developed economy by 2047. He expressed that this vision aligns with the transformative potential of biosolutions. As one of the fastest-growing economies, India is poised to leverage biosolutions to foster sustainable growth and resource efficiency.
Mohan underscored the importance of merging global scientific innovations with locally relevant solutions, which can facilitate advancements in key national priorities, including food security, energy transition, and environmental sustainability. The integration of biosolutions into India’s growth strategy can drive inclusive economic and social development.
Continuing Engagement and Future Prospects
The Novo Group India Day is part of the ongoing efforts to deepen the Group’s engagement in India through philanthropy, industry collaboration, and investment. This event followed the expansion of each entity’s presence in the country over recent years, demonstrating the Group’s dedication to long-term involvement in the region.
The event concluded with an insightful address from Christoffer Søderberg, managing partner and head of Principal Investments at Novo Holdings. He highlighted India’s significance as a long-term investment market and innovation partner, emphasizing the potential for continued collaboration between the Novo Group and Indian stakeholders.
Conclusion
The inaugural Novo Group India Day marked a significant milestone in the Group’s journey in India, reinforcing its commitment to health, science, and sustainability. By fostering partnerships and driving innovation, the Novo Group is well-positioned to contribute to the evolution of India’s healthcare landscape and address pressing challenges. As the Group looks to the future, its dedication to collaboration and sustainable growth remains unwavering.
- Key Takeaways:
- India is a critical component of the Novo Group’s long-term strategy in Asia.
- The Group’s presence encompasses philanthropy, healthcare innovation, and investment.
- Innovative treatments and biosolutions are essential for addressing healthcare needs in India.
- Collaboration with local partners will enhance sustainability and economic development.
- The vision for India as a developed economy aligns with Novo Group’s strategic objectives.
Read more → www.pharmabiz.com